Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
353.6 BRL | +3.69% | +3.44% | +31.36% |
05-30 | Citigroup Adjusts Price Target on Chubb to $278 From $275 | MT |
05-23 | BofA Upgrades Chubb to Neutral From Underperform, Raises Price Target to $266 From $244 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Sales forecast by analysts have been recently revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Multiline Insurance & Brokers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+31.36% | 114B | - | ||
+11.43% | 113B | B- | ||
+9.56% | 102B | B | ||
+8.33% | 75.49B | C+ | ||
+13.30% | 20.47B | A- | ||
-4.01% | 12.13B | B- | ||
+6.88% | 10.96B | A- | ||
+4.07% | 10.15B | A | ||
+12.28% | 9.34B | A- | ||
+16.82% | 9.1B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CB Stock
- C1BL34 Stock
- Ratings Chubb Limited